MCLA-117, a human bispecific IgG antibody which targets CLL-1 and CD3, was generated by Merus B.V. and demonstrated potent cytotoxicity against primary AML cells at a low effector to target ratios in vitro [47]. The gene discussed is CLEC12A; the disease is acute myeloid leukemia.